Provident Investment Management, Inc. Supernus Pharmaceuticals, Inc. Transaction History

Provident Investment Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 06, 2019	SELL	$25.47 - $33.37 $18.5 Million - $24.2 Million	-726,333 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$29.96 - $38.87 $2.64 Million - $3.42 Million	88,099 Added 13.8%	726,333 $24 Million
Q1 2019 May 13, 2019	BUY	$32.77 - $41.99 $2.45 Million - $3.14 Million	74,730 Added 13.26%	638,234 $22.4 Million
Q4 2018 Feb 11, 2019	SELL	$30.84 - $49.51 $825,432 - $1.33 Million	-26,765 Reduced 4.53%	563,504 $18.7 Million
Q3 2018 Nov 13, 2018	BUY	$42.7 - $56.55 $2.01 Million - $2.66 Million	47,075 Added 8.67%	590,269 $29.7 Million
Q2 2018 Aug 09, 2018	BUY	$44.1 - $59.85 $161,317 - $218,931	3,658 Added 0.68%	543,194 $32.5 Million
Q1 2018 Apr 23, 2018	BUY	$37.15 - $46.9 $20 Million - $25.3 Million	539,536 New	539,536 $24.7 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Provident Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Provident Investment Management, Inc. with notifications on news.